Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07235059
PHASE1

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of OJR520 in Healthy Volunteers and Participants With Chronic Kidney Disease

Sponsor: Novartis Pharmaceuticals

View on ClinicalTrials.gov

Summary

The purpose of this first-in-human (FIH) study is to evaluate safety, tolerability, pharmacokinetic (PK) of OJR520.

Official title: A Participant- and Investigator--Blinded, Placebo- Controlled, Randomized, Multipart, Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of OJR520 in Healthy Volunteers and Participants With Chronic Kidney Disease

Key Details

Gender

All

Age Range

18 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

112

Start Date

2025-11-20

Completion Date

2027-07-19

Last Updated

2026-03-23

Healthy Volunteers

Yes

Interventions

DRUG

OJR520

Participants will receive OJR520 in different dose levels.

OTHER

Placebo

Participants will receive OJR520 matching placebo.

Locations (2)

Quotient Sciences Sea View

Miami, Florida, United States

Novartis Investigative Site

Berlin, Germany